2004
DOI: 10.1128/jvi.78.22.12497-12507.2004
|View full text |Cite
|
Sign up to set email alerts
|

ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy

Abstract: (14), Jamaica, and the Dominican Republic (13, 17). The rapid geographic expansion of the virus is attributed to movement by viremic birds during local and migratory flight behavior. To date, there is no effective drug treatment against WN virus infection and surveillance and mosquito control measures have not significantly influenced the number of human infections (27). A vaccine against WN virus represents an important approach to the prevention and control of this emerging disease.The ChimeriVax technology … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
150
1
2

Year Published

2005
2005
2017
2017

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 186 publications
(161 citation statements)
references
References 32 publications
(39 reference statements)
4
150
1
2
Order By: Relevance
“…With no specific treatment against WNV infection, precedence is given to developing an effective vaccine against it. A number of WNV vaccine candidates had been evaluated in animal models and approved for usage on horses (17)(18)(19)(20)(21)(22). These include an inactivated WNV horse vaccine and a recombinant vaccine using the canarypox virus to express WNV Ags (18,19).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…With no specific treatment against WNV infection, precedence is given to developing an effective vaccine against it. A number of WNV vaccine candidates had been evaluated in animal models and approved for usage on horses (17)(18)(19)(20)(21)(22). These include an inactivated WNV horse vaccine and a recombinant vaccine using the canarypox virus to express WNV Ags (18,19).…”
Section: Discussionmentioning
confidence: 99%
“…These include an inactivated WNV horse vaccine and a recombinant vaccine using the canarypox virus to express WNV Ags (18,19). Another study used a chimeric live virus incorporating the NY99 WNV prM (precursor membrane protein), and the E gene inserted into the infectious clone backbone of the yellow fever or dengue virus serotype 4 have been constructed and serotype 4 and is now pending evaluation in clinical trials (21)(22). However, the risk of immune enhancement of heterologous flavivirus infection with inactivated virus and the legitimate safety concerns with the chimeric flaviviruses are highly debatable.…”
Section: Discussionmentioning
confidence: 99%
“…24 Therefore, the prM and E proteins of the YFV vaccine strain were replaced with the WNV prM and E proteins in chimeric viruses, which have shown promise for vaccine development. 58 The different stages of the WNV replication cycle could be used to develop new antiviral therapies. One strategy is the blocking of the virus entry utilizing antibodies directed against the E protein, subsequently inhibiting receptor binding and thus preventing the internalization of the virion into the host cell.…”
Section: Antiviral Strategiesmentioning
confidence: 99%
“…To reduce neurovirulence and further attenuate the virus, 3 additional mutations were added on the E protein [31]. ChimeriVax-WN02induced strong neutralising antibody and T cell responses as well as protected hamsters, mice and rhesus macaques against WNV challenges [31,32]. A phase I study in volunteers revealed that ChimeriVax-WN02 was well tolerated and highly immunogenic [33].…”
Section: Live Attenuatedmentioning
confidence: 99%
“…Genes encoding the WNV prM and E protein were inserted into the backbone of the yellow fever virus (YFV) 17D vaccine strain. To reduce neurovirulence and further attenuate the virus, 3 additional mutations were added on the E protein [31]. ChimeriVax-WN02induced strong neutralising antibody and T cell responses as well as protected hamsters, mice and rhesus macaques against WNV challenges [31,32].…”
Section: Live Attenuatedmentioning
confidence: 99%